Comparative Pharmacology
Head-to-head clinical analysis: VITAMIN A versus VITAMIN A SOLUBILIZED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VITAMIN A versus VITAMIN A SOLUBILIZED.
VITAMIN A vs VITAMIN A SOLUBILIZED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin A (retinol) is converted to retinal and retinoic acid, which bind to nuclear receptors (RARs and RXRs) to regulate gene expression involved in cell growth, differentiation, and vision.
Vitamin A (retinol) is essential for vision, immune function, and cellular differentiation. It binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating gene transcription. In the retina, it forms rhodopsin, a light-sensitive pigment necessary for low-light vision.
Adults: 10000-50000 IU/day orally for deficiency; up to 100000 IU/day for severe deficiency short-term. Intramuscular: 50000 IU daily for 3 days, then 50000 IU weekly for 2-3 months.
Vitamin A solubilized: 10,000-50,000 IU orally once daily for deficiency. For severe deficiency: 100,000 IU intramuscularly once, repeated in 24 hours if needed. Maintenance: 10,000-20,000 IU orally daily.
None Documented
None Documented
Clinical Note
moderateVitamin A + Digoxin
"Vitamin A may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVitamin A + Digitoxin
"Vitamin A may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVitamin A + Deslanoside
"Vitamin A may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVitamin A + Acetyldigitoxin
"Vitamin A may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of vitamin A is variable, ranging from 10 to 100 days due to extensive storage in the liver; in individuals with adequate hepatic stores, the half-life is approximately 50–100 days, but in deficiency states, it may be shorter (10–20 days). Clinically, this long half-life supports once-daily dosing for chronic therapy.
Terminal half-life: 12.5–60 days (mean ~25 days) in adults; prolonged in hypervitaminosis A. Clinical context: Accumulation risk with chronic use due to slow elimination.
Vitamin A is eliminated primarily via biliary excretion into feces as metabolites (approximately 80–90%), with renal excretion accounting for less than 10% of unchanged drug and metabolites. A small fraction undergoes enterohepatic circulation.
Renal: <1% as unchanged drug; biliary/fecal: >90% as metabolites and conjugated forms.
Category C
Category C
Vitamin A
Vitamin A